These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 21092287

  • 1. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I, González-Delgado CA, Valenzuela-Silva CM, Díaz-Machado A, Cruz-Díaz M, Nodarse-Cuní H, Pérez-Pérez O, Bermúdez-Badell CH, Ferrero-Bibilonia J, Páez-Meireles R, Bello-Rivero I, Castro-Odio FR, López-Saura PA, FarmaPEG Study Group.
    BMC Pharmacol; 2010 Nov 23; 10():15. PubMed ID: 21092287
    [Abstract] [Full Text] [Related]

  • 2. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers.
    Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva C, Hernandez-Bernal F, Ferrero-Bibilonia J, Soto-Hernandez R, Cervantes-Llano M, Ducongé J, Correa-Fernandez A, Olivera-Ruano L, Lopez-Saura P.
    Drugs R D; 2004 Nov 23; 5(5):271-80. PubMed ID: 15357626
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
    Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM.
    Br J Clin Pharmacol; 1998 Dec 23; 46(6):563-70. PubMed ID: 9862245
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study.
    Patel TB, Pequignot E, Parker SH, Leavitt MC, Greenberg HE, Kraft WK.
    Int J Clin Pharmacol Ther; 2007 Mar 23; 45(3):161-8. PubMed ID: 17416111
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
    Foster GR.
    Expert Opin Pharmacother; 2003 May 23; 4(5):685-91. PubMed ID: 12739994
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Population PK-PD Model of Pegylated Interferon Alfa-2a in Healthy Korean Men.
    Jung YS, Chae D, Park K.
    J Pharm Sci; 2018 Dec 23; 107(12):3171-3178. PubMed ID: 30179597
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
    Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L.
    J Clin Oncol; 2001 Mar 01; 19(5):1312-9. PubMed ID: 11230473
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y, Zhang Z, Fan K, Zhang J, Shen W, Li M, Si D, Luo H, Zeng Y, Fu P, Liu C.
    Regul Pept; 2012 Jan 10; 173(1-3):74-81. PubMed ID: 21985916
    [Abstract] [Full Text] [Related]

  • 20. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR.
    Semin Liver Dis; 2004 Jan 10; 24 Suppl 2():33-8. PubMed ID: 15346244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.